Marisa Wexler, MS, senior science writer —

Soliris (eculizumab), an approved treatment for atypical hemolytic uremic syndrome (aHUS), is now available to patients in China, AstraZeneca announced. “This milestone reflects our ambition to bring transformative, rare disease medicines to the significant number of patients and families living with rare diseases in China who currently have…

When treating atypical hemolytic uremic syndrome (aHUS) with Soliris (eculizumab), the medication can be safely discontinued after the immune system disorder is in remission, a new study shows. Moreover, the results suggest that stopping Soliris, rather than continuing treatment indefinitely, can lead to substantial cost savings without notably…

Sirnaomics has launched preclinical testing of a first candidate therapy developed with its GalAhead platform for complement-mediated diseases, including atypical hemolytic uremic syndrome (aHUS). The therapy, STP144G, is one of four experimental treatments developed with the proprietary Sirnaomics platform. Data from these early studies are expected to eventually…

Eight cases of atypical hemolytic uremic syndrome (aHUS) that occurred in people with underlying conditions that could have prompted increased activity of the complement cascade — a part of the immune system that is thought to drive aHUS — were described in a recent report. “The cases described…

The case of a woman who developed atypical hemolytic uremic syndrome (aHUS) during pregnancy was described in a recent report, which highlights the need to measure the levels of the ADAMTS13 enzyme to differentiate aHUS from similar conditions. The report, “A Case of Atypical Hemolytic Uremic…

The European Commission is expected to propose a new governing framework for health data next month, called the European Health Data Space (EHDS), with the aim of connecting national health systems to facilitate secure and efficient transfer of data across systems in different European nations. The move is expected to…

Five children in India who developed or had a relapse of atypical hemolytic uremic syndrome (aHUS) in the summer of 2021 all appeared to have experienced mild COVID-19 infection, which is thought to have triggered the rare immune system disorder. Those are the findings of a recent report by…

Ultomiris (ravulizumab) was reportedly used for the first time to control atypical hemolytic uremic syndrome (aHUS) in a patient who received a kidney transplant from a living donor, according to a group of doctors in Germany. “We provide first evidence for the efficacy of [Ultomiris] to prevent recurrence…

Because viral infections can worsen atypical hemolytic uremic syndrome (aHUS), researchers recommend testing patients for infections that are common following an organ transplant. They describe the case of patient, whose aHUS symptoms recurred after undergoing a kidney transplant, in their report, “Concurrent cytomegalovirus enteritis and atypical…

About four in 10 children in Egypt who have atypical hemolytic uremic syndrome (aHUS) test positive for antibodies against the complement protein factor H, a study has found. These findings highlight the importance of testing for the presence of these antibodies to ensure prompt diagnosis and treatment, according to…